Quality of life in cancer patients treated with mistletoe: a systematic review and meta-analysis

Abstract Background Mistletoe extracts are used as an adjunct therapy for cancer patients, but there is dissent as to whether this therapy has a positive impact on quality of life (QoL). Methods We conducted a systematic review searching in several databases (Medline, Embase, CENTRAL, CINAHL, PsycIn...

Full description

Bibliographic Details
Main Authors: Martin Loef, Harald Walach
Format: Article
Language:English
Published: BMC 2020-07-01
Series:BMC Complementary Medicine and Therapies
Subjects:
Online Access:http://link.springer.com/article/10.1186/s12906-020-03013-3
id doaj-5f68837519474860afa1ff644695f77e
record_format Article
spelling doaj-5f68837519474860afa1ff644695f77e2020-11-25T03:09:18ZengBMCBMC Complementary Medicine and Therapies2662-76712020-07-0120111410.1186/s12906-020-03013-3Quality of life in cancer patients treated with mistletoe: a systematic review and meta-analysisMartin Loef0Harald Walach1CHS-InstitutCHS-InstitutAbstract Background Mistletoe extracts are used as an adjunct therapy for cancer patients, but there is dissent as to whether this therapy has a positive impact on quality of life (QoL). Methods We conducted a systematic review searching in several databases (Medline, Embase, CENTRAL, CINAHL, PsycInfo, Science Citation Index, clinicaltrials.gov, opengrey.org ) by combining terms that cover the fields of “neoplasm”, “quality of life” and “mistletoe”. We included prospective controlled trials that compared mistletoe extracts with a control in cancer patients and reported QoL or related dimensions. The quality of the studies was assessed with the Cochrane Risk of Bias tool version 2. We conducted a quantitative meta-analysis. Results We included 26 publications with 30 data sets. The studies were heterogeneous. The pooled standardized mean difference (random effects model) for global QoL after treatment with mistletoe extracts vs. control was d = 0.61 (95% CI 0.41–0.81, p < 0,00001). The effect was stronger for younger patients, with longer treatment, in studies with lower risk of bias, in randomized and blinded studies. Sensitivity analyses support the validity of the finding. 50% of the QoL subdomains (e.g. pain, nausea) show a significant improvement after mistletoe treatment. Most studies have a high risk of bias or at least raise some concern. Conclusion Mistletoe extracts produce a significant, medium-sized effect on QoL in cancer. Risk of bias in the analyzed studies is likely due to the specific type of treatment, which is difficult to blind; yet this risk is unlikely to affect the outcome. PROSPERO registration CRD42019137704 .http://link.springer.com/article/10.1186/s12906-020-03013-3Meta-analysisQuality of lifeMistletoeCancerSystematic review
collection DOAJ
language English
format Article
sources DOAJ
author Martin Loef
Harald Walach
spellingShingle Martin Loef
Harald Walach
Quality of life in cancer patients treated with mistletoe: a systematic review and meta-analysis
BMC Complementary Medicine and Therapies
Meta-analysis
Quality of life
Mistletoe
Cancer
Systematic review
author_facet Martin Loef
Harald Walach
author_sort Martin Loef
title Quality of life in cancer patients treated with mistletoe: a systematic review and meta-analysis
title_short Quality of life in cancer patients treated with mistletoe: a systematic review and meta-analysis
title_full Quality of life in cancer patients treated with mistletoe: a systematic review and meta-analysis
title_fullStr Quality of life in cancer patients treated with mistletoe: a systematic review and meta-analysis
title_full_unstemmed Quality of life in cancer patients treated with mistletoe: a systematic review and meta-analysis
title_sort quality of life in cancer patients treated with mistletoe: a systematic review and meta-analysis
publisher BMC
series BMC Complementary Medicine and Therapies
issn 2662-7671
publishDate 2020-07-01
description Abstract Background Mistletoe extracts are used as an adjunct therapy for cancer patients, but there is dissent as to whether this therapy has a positive impact on quality of life (QoL). Methods We conducted a systematic review searching in several databases (Medline, Embase, CENTRAL, CINAHL, PsycInfo, Science Citation Index, clinicaltrials.gov, opengrey.org ) by combining terms that cover the fields of “neoplasm”, “quality of life” and “mistletoe”. We included prospective controlled trials that compared mistletoe extracts with a control in cancer patients and reported QoL or related dimensions. The quality of the studies was assessed with the Cochrane Risk of Bias tool version 2. We conducted a quantitative meta-analysis. Results We included 26 publications with 30 data sets. The studies were heterogeneous. The pooled standardized mean difference (random effects model) for global QoL after treatment with mistletoe extracts vs. control was d = 0.61 (95% CI 0.41–0.81, p < 0,00001). The effect was stronger for younger patients, with longer treatment, in studies with lower risk of bias, in randomized and blinded studies. Sensitivity analyses support the validity of the finding. 50% of the QoL subdomains (e.g. pain, nausea) show a significant improvement after mistletoe treatment. Most studies have a high risk of bias or at least raise some concern. Conclusion Mistletoe extracts produce a significant, medium-sized effect on QoL in cancer. Risk of bias in the analyzed studies is likely due to the specific type of treatment, which is difficult to blind; yet this risk is unlikely to affect the outcome. PROSPERO registration CRD42019137704 .
topic Meta-analysis
Quality of life
Mistletoe
Cancer
Systematic review
url http://link.springer.com/article/10.1186/s12906-020-03013-3
work_keys_str_mv AT martinloef qualityoflifeincancerpatientstreatedwithmistletoeasystematicreviewandmetaanalysis
AT haraldwalach qualityoflifeincancerpatientstreatedwithmistletoeasystematicreviewandmetaanalysis
_version_ 1724663470653177856